Get the Stockscreener App
14.60
1.08%
-0.16
Pre-market:
14.60
Avalo Therapeutics Inc stock is traded at $14.60, with a volume of 949.82K.
It is down -1.08% in the last 24 hours and down -17.70% over the past month.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
See More
Previous Close:
$14.76
Open:
$15.01
24h Volume:
949.82K
Relative Volume:
0.62
Market Cap:
$767.46M
Revenue:
$59,000
Net Income/Loss:
$-84.74M
P/E Ratio:
-2.5076
EPS:
-5.8222
Net Cash Flow:
$-59.69M
1W Performance:
+14.60%
1M Performance:
-17.70%
6M Performance:
-17.51%
1Y Performance:
+201.65%
1-Day Range:
$14.51
$15.23
1-Week Range:
$12.52
$15.23
52-Week Range:
$4.46
$24.27
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
14.60 | 767.46M | 59,000 | -84.74M | -59.69M | -5.8222 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Apr-06-26 | Initiated | Citizens | Mkt Outperform |
| Feb-02-26 | Initiated | Guggenheim | Buy |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-25 | Initiated | TD Cowen | Buy |
| Aug-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
Avalo Therapeutics advances long‑acting IL‑1β candidate AVTX-010, IND planned for 1H 2027 - TradingView
Avalo Therapeutics plans IND submission for AVTX-010 in H1 2027 - Investing.com Canada
Avalo develops longer-lasting antibody to enable less frequent dosing - Stock Titan
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody - GlobeNewswire
Avalo Therapeutics stock soars after positive LOTUS trial results - MSN
AVTX Initiates Coverage On B of A Securities -- Rating Set to Bu - GuruFocus
Avalo Therapeutics amends preferred stock terms and executive agreements - Investing.com
Avalo Therapeutics Expands Ownership Limits, Updates Executive Contracts - TipRanks
Avalo Therapeutics (AVTX) CSO logs 588-share tax-withholding transaction - Stock Titan
Avalo Therapeutics (AVTX) CLO logs tax-withholding of 1,081 shares on Form 4 - Stock Titan
Avalo Therapeutics (NASDAQ: AVTX) CFO logs tax-withholding share move - Stock Titan
[Form 4] Avalo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Avalo Therapeutics (NASDAQ: AVTX) creates Series C-1 preferred and enhances executive change-in-control pay - Stock Titan
BofA Securities Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $35 - Moomoo
This Keurig Dr Pepper Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
BofA initiates Avalo Therapeutics stock with buy rating on HS drug - Investing.com Nigeria
FMR LLC's Strategic Acquisition of Avalo Therapeutics Inc Shares - GuruFocus
AVALO THERAPEUTICS INC (AVTX) Stock Chart - ChartMill
Avalo Therapeutics: Sell-Off Could Continue If Overall Market Deteriorates Further - Seeking Alpha
Avalo Therapeutics elects directors, approves stock plan and auditor at annual meeting - Investing.com UK
Avalo Therapeutics (AVTX) holders approve ESPP, elect 7 directors and ratify Ernst & Young - Stock Titan
Avalo Therapeutics prices $375 million stock offering By Investing.com - Investing.com Nigeria
FMR LLC amendment shows 3.19M shares in Avalo Therapeutics (AVTX) - Stock Titan
Deep Track Capital, LP Acquires Significant Stake in Avalo Thera - GuruFocus
Deep Track Capital, LP Acquires Significant Stake in Avalo Therapeutics Inc - GuruFocus
Director at Avalo Therapeutics (AVTX) granted 20,100 stock options - Stock Titan
Avalo Therapeutics (AVTX) director receives grant of 20,100 stock options at $13.96 - Stock Titan
Avalo Therapeutics (AVTX) director receives 20,100 stock options at $13.96 strike - Stock Titan
Avalo Therapeutics (AVTX) director receives stock options for 20,100 shares - Stock Titan
Avalo Therapeutics (AVTX) director awarded 29,500 options at $13.96 strike - Stock Titan
Avalo Therapeutics (AVTX) director granted 20,100 stock options at $13.96 strike - Stock Titan
Avalo Therapeutics (AVTX) Edges Higher as Stock Tests Key Near-Term ResistanceBPI Bear Correction - newsline.com
AVTX: Broker-listed notice for proposed sales of 43,?33 shares (06/02/2026) - Stock Titan
Avalo Therapeutics (AVTX) CMO sells shares under 10b5-1 plan - Stock Titan
AVTX Q1 2026 Earnings: Narrower Loss Lifts Investor Sentiment Amid Continued Pre-Revenue StageOperating Margin Analysis - newsline.com
Deep Track holds 5.81% of Avalo Therapeutics (AVTX) in Schedule 13G filing - Stock Titan
AVTX News | AVALO THERAPEUTICS INC (NASDAQ:AVTX) - ChartMill
Avalo Therapeutics (AVTX) Stock Price, Quote, Charts & News - Invezz
Point72 (AVTX) reports 2.71M-share, 5.2% position in Avalo Therapeutics - Stock Titan
Avalo Therapeutics (AVTX) CSO granted 34,200 performance stock units vesting in 2028 - Stock Titan
Avalo Therapeutics (AVTX) CFO receives 39,900 PSU-linked shares in equity award - Stock Titan
Avalo Therapeutics (AVTX) CLO granted 24,300 performance-based common shares - Stock Titan
Avalo Therapeutics (AVTX) CMO receives 43,500-share performance award - Stock Titan
Performance stock units expand Avalo (NASDAQ: AVTX) CEO’s stake - Stock Titan
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Avalo Therapeutics (AVTX) Holds Steady Near Key Support LevelsRetail Driven Moves - newsline.com
AVTX Q1 2026 Earnings: Narrower-Than-Expected Loss Marks a Slight Positive SurpriseOne-Time Loss Impact - newsline.com
Avalo Therapeutics (AVTX) CMO exercises options and sells 3,000 shares under plan - Stock Titan
Avalo Therapeutics (AVTX) price target increased by 18.49% to 47.94 - MSN
UBS Group AG Has $8.68 Million Stock Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty - TipRanks
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):